Haematological Indicators of Response to Erythropoietin Therapy in Chronic Renal Failure Patients on Haemodialysis: Impact of Angiotensin-Converting Enzyme rs4343 Gene Polymorphism

References

• Vianna HR, Soares CMBM, Tavares MS, Teixeira MM, Simoes AC. [Inflammation in chronic kidney disease: the role of cytokines]. Jornal Brasileiro de Nefrologia. 2011;33(3):351–364. Portuguese. doi:10.1590/S0101-28002011000300012
   Google Scholar
• Okada R, Wakai K, Naito M, et al. Pro-/anti-inflammatory cytokine gene polymorphisms and chronic kidney disease: a Cross-Sectional Study. BMC Nephrol. 2012;13(1):2. doi:10.1186/1471-2369-13-2
   Web of Science ®Google Scholar
• Ramaprabha P, Bhuvaneswari T, Kumar R. Coagulation profiles an indicator of vascular haemostatic function in chronic renal failure patients who are on renal dialysis. Sch J App Med Sci. 2014;2(2B):592–595.
   Google Scholar
• Ribeiro S, Costa E, Belo L, Reis F, Santos-Silva A. rhEPO for the treatment of erythropoietin resistant anemia in hemodialysis patients–risks and benefits. In: Hemodialysis. IntechOpen; 2013.
   Google Scholar
• Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: third national health and nutrition examination survey. Am J Kidney Dis. 2003;41(1):1–12. doi:10.1053/ajkd.2003.50007
   PubMed Web of Science ®Google Scholar
• O’Mara NB. Anemia in patients with chronic kidney disease. Diabetes Spectr. 2008;21(1):12–19. doi:10.2337/diaspect.21.1.12
   Google Scholar
• Thomas R, Kanso A, Sedor JR. Chronic kidney disease and its complications. Prim Care. 2008;35(2):329–344. doi:10.1016/j.pop.2008.01.008
   PubMed Web of Science ®Google Scholar
• Hung S-C, Lin Y-P, Tarng D-C. Erythropoiesis-stimulating agents in chronic kidney disease: what have we learned in 25 years? J Formos Med Assoc. 2014;113(1):3–10. doi:10.1016/j.jfma.2013.09.004
   PubMed Web of Science ®Google Scholar
• Sayed-Tabatabaei F, Oostra B, Isaacs A, Van Duijn C, Witteman J. ACE polymorphisms. Circ Res. 2006;98(9):1123–1133. doi:10.1161/01.RES.0000223145.74217.e7
   PubMed Web of Science ®Google Scholar
• Jeong K-H, Lee T-W, Ihm C-G, Lee S-H, Moon J-Y. Polymorphisms in two genes, IL-1B and ACE, are associated with erythropoietin resistance in Korean patients on maintenance hemodialysis. Exp Mol Med. 2008;40(2):161. doi:10.3858/emm.2008.40.2.161
   Web of Science ®Google Scholar
• Varagunam M, McCloskey DJ, Sinnott PJ, Raftery MJ, Yaqoob MM. Angiotensin-converting enzyme gene polymorphism and erythropoietin requirement. Perit Dial Int. 2003;23(2):111–115. doi:10.1177/089686080302300203
   Web of Science ®Google Scholar
• Chung CM, Wang RY, Chen JW, et al. A genome-wide association study identifies new loci for ACE activity: potential implications for response to ACE inhibitor. Pharmacogenomics J. 2010;10(6):537–544. doi:10.1038/tpj.2009.70
   Web of Science ®Google Scholar
• Court M, Michael H. Court’s (2005–2008) Online Calculator. Tuft University Website; 2012.
   Google Scholar
• Pare L, Marcuello E, Altes A, et al. Transcription factor-binding sites in the thymidylate synthase gene: predictors of outcome in patients with metastatic colorectal cancer treated with 5-fluorouracil and oxaliplatin? Pharmacogenomics J. 2008;8(5):315–320. doi:10.1038/sj.tpj.6500469
   Web of Science ®Google Scholar
• Mostafa-Hedeab G, Mohamed AA, Thabet G, Sabry D, Salam RF, Hassen ME. Effect of MATE 1, MATE 2 and OCT1 single nucleotide polymorphisms on metformin action in recently diagnosed Egyptian type-2 diabetic patients. Biomed Pharm J. 2018;11(1):149–157. doi:10.13005/bpj/1356
   Google Scholar
• Mostafa‐Hedeab G, Saber‐Ayad MM, Latif IA, et al. Functional G1199A ABCB1 polymorphism may have an effect on cyclosporine blood concentration in renal transplanted patients. J Clin Pharm. 2013;53(8):827–833. doi:10.1002/jcph.105
   Web of Science ®Google Scholar
• Ghafil FA, Mohammad BI, Al-Janabi HS, Hadi NR, Al-Aubaidy HA. Genetic polymorphism of angiotensin converting enzyme and angiotensin II type 1 receptors and their impact on the outcome of acute coronary syndrome. Genomics. 2020;112(1):867–872. doi:10.1016/j.ygeno.2019.05.028
   Web of Science ®Google Scholar
• Ulgen MS, Ozturk O, Yazici M, et al. Association between A/C1166 gene polymorphism of the angiotensin II type 1 receptor and biventricular functions in patients with acute myocardial infarction. Circ J. 2006;70(10):1275–1279. doi:10.1253/circj.70.1275
   Web of Science ®Google Scholar
• Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am J Kidney Dis. 2010;56(3):558–565. doi:10.1053/j.ajkd.2009.12.042
   PubMed Web of Science ®Google Scholar
• Mostafa-Hedeab G. ACE2 as drug target of COVID-19 virus treatment, simplified updated review. Rep Biochem Mol Biol. 2020;9(1):97–105. doi:10.29252/rbmb.9.1.97
   Web of Science ®Google Scholar
• Kwack C, Balakrishnan VS. Unresolved issues in dialysis: managing erythropoietin hyporesponsiveness. In: Seminars in Dialysis. Wiley Online Library; 2006.
   Google Scholar
• Le Meur Y, Lorgeot V, Comte L, et al. Plasma levels and metabolism of AcSDKP in patients with chronic renal failure: relationship with erythropoietin requirements. Am J Kidney Dis. 2001;38(3):510–517. doi:10.1053/ajkd.2001.26839
   PubMed Web of Science ®Google Scholar
• Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid progenitors. J Clin Invest. 1997;100(9):2310–2314. doi:10.1172/JCI119769
   PubMed Web of Science ®Google Scholar
• Savin M, Hadzibulic E, Damnjanović T, Santric V, Stankovic S. Association of I/D angiotensin-converting enzyme genotype with erythropoietin stimulation in kidney failure. Arch Biol Sci. 2017;69(1):15–22. doi:10.2298/ABS160303051S
   Google Scholar
• Sharples EJ, Varagunam M, Sinnott PJ, McCloskey DJ, Raftery MJ, Yaqoob MM. The effect of proinflammatory cytokine gene and angiotensin-converting enzyme polymorphisms on erythropoietin requirements in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int. 2006;26(1):64–68. doi:10.1177/089686080602600110
   Web of Science ®Google Scholar
• Hatano M, Yoshida T, Mimuro T, et al. [The effects of ACE inhibitor treatment and ACE gene polymorphism on erythropoiesis in chronic hemodialysis patients]. Nihon Jinzo Gakkai Shi. 2000;42(8):632–639. Japanese.
   Google Scholar
• Kiss Z, Ambrus C, Kulcsár I, Szegedi J, Kiss I. Effect of angiotensin-converting enzyme gene insertion/deletion polymorphism and angiotensin-converting enzyme inhibition on erythropoiesis in patients on haemodialysis. J Renin Angiotensin Aldosterone Syst. 2015;16(4):1021–1027. doi:10.1177/1470320314535276
   Web of Science ®Google Scholar
• Al-Radeef MY, Fawzi HA, Allawi AA. ACE gene polymorphism and its association with serum erythropoietin and hemoglobin ‎in Iraqi hemodialysis patients. Appl Clin Genet. 2019;12:107–112. doi:10.2147/TACG.S198992
   Web of Science ®Google Scholar
• Fisher RA. XXI.—On the dominance ratio. Proc R Soc Edinb. 1923;42:321–341. doi:10.1017/S0370164600023993
   Google Scholar
• Doherty PC, Zinkernagel RM. Enhanced immunological surveillance in mice heterozygous at the H-2 gene complex. Nature. 1975;256(5512):50–52. doi:10.1038/256050a0
   Web of Science ®Google Scholar
• Penn DJ, Damjanovich K, Potts WK. MHC heterozygosity confers a selective advantage against multiple-strain infections. Proc Natl Acad Sci. 2002;99(17):11260–11264. doi:10.1073/pnas.162006499
   PubMed Web of Science ®Google Scholar
• Ferreira A, Marguti I, Bechmann I, et al. Sickle hemoglobin confers tolerance to Plasmodium infection. Cell. 2011;145(3):398–409. doi:10.1016/j.cell.2011.03.049
   PubMed Web of Science ®Google Scholar
• Xu K, Kosoy R, Shameer K, et al. Genome-wide analysis indicates association between heterozygote advantage and healthy aging in humans. BMC Genet. 2019;20(1):52. doi:10.1186/s12863-019-0758-4
   Web of Science ®Google Scholar
• Pincus MR, Abraham NZ Jr, Carty RP. 20 Clinical enzymology. In: Henry’s Clinical Diagnosis and Management by Laboratory Methods E-Book. Saunders; 2011:273. ISBN-10:1437709745
   Google Scholar
• Kumari S, Sharma N, Thakur S, Mondal PR, Saraswathy KN. Beneficial role of D allele in controlling ACE levels: a study among Brahmins of north India. J Genet. 2016;95(2):291–295. doi:10.1007/s12041-016-0649-7
   Web of Science ®Google Scholar
• Paillard F, Chansel D, Brand E, et al. Genotype-phenotype relationships for the renin-angiotensin-aldosterone system in a normal population. Hypertension. 1999;34(3):423–429. doi:10.1161/01.HYP.34.3.423
   PubMed Web of Science ®Google Scholar
• Williams AG, Rayson MP, Jubb M, World M, Woods D, Hayward M. The ACE gene and muscle performance. Nature. 2000;403(6770):614. doi:10.1038/35001141
   Web of Science ®Google Scholar
• Zhu X, Bouzekri N, Southam L, et al. Linkage and association analysis of angiotensin I–converting enzyme (ACE)–gene polymorphisms with ACE concentration and blood pressure. Am J Hum Genet. 2001;68(5):1139–1148. doi:10.1086/320104
   PubMed Web of Science ®Google Scholar
• Firouzabadi N, Shafiei M, Bahramali E, Ebrahimi SA, Bakhshandeh H, Tajik N. Association of angiotensin-converting enzyme (ACE) gene polymorphism with elevated serum ACE activity and major depression in an Iranian population. Psychiatry Res. 2012;200(2–3):336–342. doi:10.1016/j.psychres.2012.05.002
   PubMed Web of Science ®Google Scholar
• Schüler R, Osterhoff MA, Frahnow T, et al. High-saturated-fat diet increases circulating angiotensin-converting enzyme, which is enhanced by the rs4343 polymorphism defining persons at risk of nutrient-dependent increases of blood pressure. J Am Heart Assoc. 2017;6(1):e004465.
   PubMed Web of Science ®Google Scholar
• Mizuiri S, Hemmi H, Kumanomidou H, et al. Angiotensin-converting enzyme (ACE) I/D genotype and renal ACE gene expression. Kidney Int. 2001;60(3):1124–1130. doi:10.1046/j.1523-1755.2001.0600031124.x
   PubMed Web of Science ®Google Scholar
• Elshamaa MF, Sabry SM, Bazaraa HM, et al. Genetic polymorphism of ACE and the angiotensin II type1 receptor genes in children with chronic kidney disease. J Inflamm. 2011;8(1):20. doi:10.1186/1476-9255-8-20
   Google Scholar
• Nand N, Deshmukh A, Joshi S, Sachdeva M. Role of ACE and IL-1β gene polymorphisms in erythropoeitin hyporesponsive patients with chronic kidney disease with anemia. J Assoc Physicians India. 2017;65(2):32–36.
   Google Scholar
• Ng T. Recombinant erythropoietin in clinical practice. Postgrad Med J. 2003;79(933):367–376. doi:10.1136/pmj.79.933.367
   PubMed Web of Science ®Google Scholar
• Inrig JK, Bryskin SK, Patel UD, Arcasoy M, Szczech LA. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers, and soluble erythropoietin receptors. BMC Nephrol. 2011;12(1):67. doi:10.1186/1471-2369-12-67
   Web of Science ®Google Scholar
• Khankin EV, Mutter WP, Tamez H, Yuan H-T, Karumanchi SA, Thadhani R. Soluble erythropoietin receptor contributes to erythropoietin resistance in end-stage renal disease. PLoS One. 2010;5(2):e9246. doi:10.1371/journal.pone.0009246
   Web of Science ®Google Scholar
• Venkatesha S, Toporsian M, Lam C. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006;12(6):642–649. doi:10.1038/nm1429
   PubMed Web of Science ®Google Scholar
• Cançado RD, Chiattone CS. [Anemia of chronic disease]. Rev Bras Hematol Hemoter. 2002;24(2):127–136. Portuguese. doi:10.1590/S1516-84842002000200009
   Google Scholar
• Macdougall IC, Cooper AC. Erythropoietin resistance: the role of inflammation and pro‐inflammatory cytokines. Nephrol Dial Transpl. 2002;17(suppl_11):39–43. doi:10.1093/ndt/17.suppl_11.39
   PubMed Web of Science ®Google Scholar
• Betjes MG, Huisman M, Weimar W, Litjens NH. Expansion of cytolytic CD4+ CD28− T cells in end-stage renal disease. Kidney Int. 2008;74(6):760–767. doi:10.1038/ki.2008.301
   Web of Science ®Google Scholar
• Shih YJ, Baynes RD, Hudson BG, Flowers CH, Skikne BS, Cook JD. Serum transferrin receptor is a truncated form of tissue receptor. J Biol Chem. 1990;265(31):19077–19081. doi:10.1016/S0021-9258(17)30627-0
   Web of Science ®Google Scholar
• Andrews NC. A genetic view of iron homeostasis. In: Seminars in Hematology. Elsevier; 2002.
   Google Scholar
• Harford, J.B, Rouault TA, Klausner RD. The control of cellular iron homeostasis. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron metabolism in health and disease. Philadelphia: The W. B. Saunders Co; 1994:123–149.
   Google Scholar
• Cook J, Skikne B, Baynes R. Serum transferrin receptor. Annu Rev Med. 1993;44(1):63–74. doi:10.1146/annurev.me.44.020193.000431
   Google Scholar
• Skikne BS. Serum transferrin receptor. Am J Hematol. 2008;83(11):872–875. doi:10.1002/ajh.21279
   Web of Science ®Google Scholar
• Ferguson BJ, Skikne BS, Simpson KM, Baynes RD, Cook JD. Serum transferrin receptor distinguishes the anemia of chronic disease from iron deficiency anemia. J Lab Clin Med. 1992;119(4):385–390.
   PubMed Web of Science ®Google Scholar